Investing.com - Financial Markets Worldwide

European Commission approves Merck’s Capvaxive vaccine for adults

Published 26/03/2025, 13:06
European Commission approves Merck’s Capvaxive vaccine for adults
MRK
1.17%

Investing.com -- Merck & Co (NYSE:MRK)., the pharmaceutical company based in Rahway, New Jersey, has received approval from the European Commission for its Capvaxive pneumococcal disease vaccine.

The approval, announced on Wednesday, allows the use of the 21-valent conjugate vaccine for immunization in adults aged 18 and older. This vaccine is used for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae.

The U.S. Food and Drug Administration had previously approved Capvaxive in June of the prior year.

This vaccine is now authorized for use in both the United States and Europe, expanding the potential patient population who can benefit from this preventative measure against pneumococcal disease.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.